Cocrystal Pharma, Inc.
COCP
$1.49
-$0.06-3.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -33.24% | -37.17% | |||
| Gross Profit | 33.24% | 37.17% | |||
| SG&A Expenses | -17.77% | -33.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.52% | -35.94% | |||
| Operating Income | 27.52% | 35.94% | |||
| Income Before Tax | 29.55% | 33.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.55% | 33.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.55% | 33.87% | |||
| EBIT | 27.52% | 35.94% | |||
| EBITDA | 27.67% | 36.11% | |||
| EPS Basic | 29.53% | 33.88% | |||
| Normalized Basic EPS | 29.51% | 33.88% | |||
| EPS Diluted | 29.53% | 33.88% | |||
| Normalized Diluted EPS | 29.51% | 33.88% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||